22-May-2024

Osteoporosis Drugs Market Projected Significant Growth at a 3.5% CAGR Through 2032

The Osteoporosis Drugs Market is anticipated to grow significantly, with an expected market size of USD 9.8 billion by 2032, up from USD 7 billion in 2022, reflecting a CAGR of 3.5% during the forecast period from 2023 to 2032. This growth is driven by several factors, including the increasing prevalence of osteoporosis due to aging populations and lifestyle factors such as sedentary behavior, alcohol consumption, and smoking. Technological advancements in drug development, including new drug delivery systems and personalized medicine approaches, are enhancing the effectiveness of osteoporosis treatments.

However, the market faces challenges such as the high cost and long development times of new drugs, as well as safety concerns related to potential side effects like atypical fractures and osteonecrosis of the jaw. Patent expirations and the subsequent introduction of generic versions also pose significant competition, impacting the profitability of original drug manufacturers.

Recent developments in the market include the approval of new drugs and biosimilars, such as denosumab by Enzene Biosciences and Livogiva by Theramex, which aim to provide more treatment options for patients. Additionally, ongoing research and development efforts are focused on discovering new drug candidates and improving existing therapies to better address the needs of osteoporosis patients.

Key Takeaways

The global osteoporosis drugs market size is expected to grow from USD 7.0 billion in 2022 to USD 9.8 billion by 2032, with a CAGR of 3.5%.
The Bisphosphonates segment led the market growth during the forecast period.
The rank ligand inhibitors segment is expected to expand at the fastest rate during the forecast period.
The oral route of administration dominates the global osteoporosis drugs market.
The hospital pharmacies segment is projected to grow at a faster rate during the forecast period.
Increasing healthcare expenditure is a major driver of the osteoporosis drug market.
Adverse effects of anti-inflammatory medications are hampering the market’s expansion.
Expanding healthcare sectors in emerging economies contribute to the growth of the osteoporosis drug industry.
Technological advancements have led to new and effective diagnostic methods for osteoporosis screening.
Injectable osteoporosis medications are expected to experience faster growth during the forecast period.
COVID-19 has disrupted or delayed treatment for many osteoporosis patients.
North America holds the largest share in the global osteoporosis drugs market.

Get Sample PDF Report: https://market.us/report/osteoporosis-drugs-market/request-sample/

Osteoporosis Drugs Market Key Segments

By Product

Bisphosphonates
Parathyroid Hormone Therapy Drugs
Calcitonin
Selective Estrogen Receptor Modulators
RANK Ligand Inhibitor
Others

By Route of Administration

Oral
Injectable

By Distribution Channel

Retail Pharmacies
Hospital Pharmacies
Online Sales

Key Regions

North America (The US, Canada, Mexico)
Western Europe (Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, Rest of Western Europe)
Eastern Europe (Russia, Poland, The Czech Republic, Greece, Rest of Eastern Europe)
APAC (China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, Rest of APAC)
Latin America (Brazil, Colombia, Chile, Argentina, Costa Rica, Rest of Latin America)
Middle East & Africa (Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, Rest of MEA)

Buy Directly: https://market.us/purchase-report/?report_id=22087

Key Players Analysis

Amgen Inc. is a key player in the osteoporosis drugs market with its product, Prolia (denosumab). Prolia has demonstrated significant efficacy in reducing fracture risk in postmenopausal women with osteoporosis. A real-world study involving nearly 500,000 patients showed that Prolia was more effective than alendronate, another commonly prescribed treatment, in reducing hip fractures by 36% and nonvertebral fractures by 43%. Prolia generated $4 billion in revenue in 2023, marking a 12% increase from the previous year.

Eli Lilly and Company is actively engaged in the osteoporosis treatment market with its drug, Forteo (teriparatide). Forteo is a daily injectable medication that helps increase bone density and reduce the risk of fractures. The company focuses on innovative solutions and extensive clinical research to enhance patient outcomes. In recent years, Eli Lilly has seen consistent growth in its osteoporosis segment, contributing to its robust revenue streams and market presence.

Hoffmann-La Roche AG, known for its comprehensive pharmaceutical portfolio, includes Boniva (ibandronate) in its osteoporosis drugs lineup. Boniva is used primarily for the treatment and prevention of postmenopausal osteoporosis, reducing the risk of spine fractures. Roche’s commitment to advanced research and development ensures continuous improvements in osteoporosis treatment efficacy. The company remains a competitive force in the global osteoporosis market, leveraging its extensive R&D capabilities.

Merck & Co., Inc. offers Fosamax (alendronate), one of the most widely prescribed bisphosphonates for osteoporosis. Fosamax helps prevent bone fractures by inhibiting bone resorption. Merck’s strategic focus on enhancing patient access to effective treatments and ongoing research initiatives supports its strong position in the osteoporosis market. The company’s osteoporosis segment continues to grow, driven by innovations and strong market demand.

Novartis AG, through its Sandoz division, has introduced biosimilars such as Jubbonti, which is equivalent to Amgen’s Prolia. This entry strengthens Novartis’s position in the osteoporosis market by providing cost-effective alternatives to existing treatments. Novartis’s focus on biosimilars aligns with its broader strategy to expand access to affordable medications. The approval of Jubbonti marks a significant milestone, enhancing competition and patient choice in the osteoporosis sector.

Osteoporosis Drugs Market Key Players:

Amgen Inc.
Eli Lilly and Company
Hoffmann-La Roche AG
Mark and Co. Inc.
Novartis AG
Pfizer Inc.
Radius Health Inc.
Teva Pharmaceutical Industries Ltd.
Novo Nordisk A\S
UCB
Other key players

Osteoporosis Drugs Market Report Scope >> Market Value (2022): USD 7.0 Billion || Forecast Revenue (2032): USD 9.8 Billion || CAGR (2024-2033): 3.5% || Base Year Estimation: 2023 || Historic Period: 2019-2022 || Forecast Period: 2024-2033.

Inquire More about report: https://market.us/report/osteoporosis-drugs-market/#inquiry

About Market.US

Market.US is renowned for its comprehensive market research and analysis, providing customized and syndicated reports to a global clientele. Specializing in a variety of sectors, they offer strategic insights and detailed market forecasts, assisting businesses in making informed decisions. With a focus on innovation and accuracy, Market.US supports clients in over 126 countries, and maintains a strong repeat customer rate, underscoring their commitment to quality and client satisfaction. Their team excels in delivering exceptional research services, ensuring that no detail is overlooked in any target market.

Contact Details
Market.us (Powered By Prudour Pvt. Ltd.)
Contact No: +1 718 618 4351.
Email: inquiry@market.us
Blog: https://medicalmarketreport.com/

View More Trending Reports

Chromatography Software Market Expected to Grow to USD 3.3 Billion by 2033

Automated Whole-Breast Ultrasound Market Forecasted to Reach USD 10.7 Billion by 2033